MHRA-100475-PIP01-22-M01 (update)

Key Facts

Active Substance
  • Neisseria meningitidis serogroup A polysaccharide conjugated to tetanus toxoid
  • Neisseria meningitidis serogroup C polysaccharide conjugated to tetanus toxoid
  • Neisseria meningitidis serogroup Y polysaccharide conjugated to tetanus toxoid
  • Neisseria meningitidis serogroup W polysaccharide conjugated to tetanus toxoid
Invented Name
  • MenQuadfi
  • MenQuadfi
PIP Number MHRA-100475-PIP01-22-M01 (update)
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Solution for injection
Therapeutic area
Therapeutic area:
  • Vaccines
Conditions / Indications
Conditions / Indications:
  • Prevention of invasive meningococcal disease
Route(s) of administration
Route(s) of administration:
  • Intramuscular use
PIP applicant
Decision Type
Decision Type
PM: decision on the application for modification of an agreed paediatric investigation plan.
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):Neisseria meningitidis serogroup A polysaccharide conjugated to tetanus toxoidNeisseria meningitidis serogroup C polysaccharide conjugated to tetanus toxoidNeisseria meningitidis serogroup Y polysaccharide conjugated to tetanus toxoidNeisseria meningitidis serogroup W polysaccharide conjugated to tetanus toxoid.pdf
Published Date 30/06/2023